Financial research concept

Medical Devices CGM Comparable Sales Growth

measures comparable sales growth in Abbott's continuous glucose monitoring products.

By Lee BaileyPublished Oct 2, 2026

Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date: Oct 2, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context: 10 connected conceptsPart of the reviewed Medical Device Portfolio Growth; issuer definitions remain distinct where disclosed.
Company examples: 1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.

CGM is narrower than the Diabetes Care franchise
Reported and comparable growth also differ
Part of the Medical Device Portfolio Growth
See It in Company Research
Continue Research

Medical Devices CGM comparable sales growth measures year-over-year growth in Abbott's continuous glucose monitor sales on the company's comparable basis.

Abbott reported 9.5% comparable CGM sales growth in the second quarter of 2026.

Reported CGM sales growth was 11.0%.

CGM is narrower than the Diabetes Care franchise

Diabetes Care includes the broader franchise, while the CGM metric isolates Abbott's continuous glucose monitoring products.

The two growth rates should not be substituted.

Reported and comparable growth also differ

Foreign-exchange and other specified comparability effects can create a gap between reported and comparable growth.

Read it with Diabetes Care comparable growth and Medical Devices comparable growth.

Primary source: Abbott Q2 2026 earnings release filed with the SEC.

Part of the Medical Device Portfolio Growth

Connects Abbott's comparable Medical Devices growth with franchise-level growth, continuous glucose monitoring, geographic mix and the 2026 Electrophysiology/Structural Heart reclassification.

Browse the full operating model in Company Analysis →

Where this concept fits

Diabetes and continuous glucose monitoringCurrent relationship
Diabetes Care growth captures the broader franchise, while CGM comparable growth isolates the continuous-glucose-monitor platform that drives much of the franchise's expansion.
CGM Comparable GrowthCurrent conceptDiabetes Care Growth
Portfolio and geographic growth
Total Medical Devices comparable sales growth provides the portfolio baseline, while U.S. versus international comparable growth shows how the aggregate result is distributed geographically.
Medical Devices Comparable Growth U.S. vs. International Growth
Cardiovascular franchise mix
Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation growth show which cardiovascular and neuromodulation franchises are driving or lagging total Medical Devices growth.
Electrophysiology Growth Heart Failure Growth Neuromodulation Growth Rhythm Management Growth Structural Heart Growth Vascular Growth

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

ABTOpen operating-model research →10 of 10 reviewed concepts in Medical Device Portfolio GrowthDiabetes and continuous glucose monitoring2 of 2 bridge concepts supportedContinue through this bridge:Diabetes Care Growth

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare medical device portfolio growth

Compare continuous-glucose-monitor growth separately from the broader Diabetes Care franchise and reported FX-affected growth.

Continue research

Explore more topics in the Financial Research Encyclopedia.